Fuel Progress
Dive into the collective wisdom, insights, and strategies from experts in pharma and biotech.
OVN Podcasts
Kirk Shepard
Humans Beyond the Algorithm: Hiring for Oncology’s Future
Kirk Shepard
How Cross-Functional Teams Reshape Cancer Care
Kirk Shepard
Trust, Transparency & Timelines: Advancing Cancer Care
Ramin Farhood
Busting Silos: Building the Future of Oncology Drug Development
Featured Podcasts
Monty Pal
Unlocking the Future of Cancer Care: Precision Medicine, AI and the Patient Voice with Dr. Stacy Gray
Rebecca Previs
Navigating the Future of CDXs in Oncology
Monty Pal
Translating Discovery: Shaping Tomorrow’s Prostate Cancer Therapies
Monty Pal
BONUS: The Future of Cancer Surgery: Innovations, AI and Remote Robotics
Monty Pal
How Mentorship Sparks Innovation: A Conversation with Dr. Wesley Yip
Monty Pal
How Team Science Fuels Cancer Breakthroughs: A Conversation with Dr. Marcel van den Brink
Trending on OVN
01
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Apr 1st • 30 mins read
02
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD
Outcome measures for oncology alternative payment models: practical considerations and recommendations
Dec 1st • 10 mins read
03
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Jan 7th • 8 mins read
04
R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Aug 2nd • 8 mins read
05
Yuan Zhang, Xu Liu, Ying-Qin Li, Ling-Long Tang, Lei Chen, Jun Ma
A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
Aug 12th • 10 mins read
06
Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
Sep 6th • 20 mins read
Leon Rozen
Michael Pietrack
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
In this episode of The Authority Company Podcast, host Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard, co-authors of Voices of Oncology and co-founders of the...
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
We are proud to announce the forthcoming publication of Voices of Oncology — a first-of-its-kind collection of expert perspectives from across the oncology ecosystem, arriving July 2025 in partnership with...
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
At the heart of the Oncology Voice Network (OVN) is a powerful mission: to unify oncology leaders across disciplines and accelerate the development of solutions that truly serve patients. Driving...